| Typicality: | 0.327 |
| Saliency: | 0.180 |
| for gs-4774 | 3 | transitive-object |
| during the third quarter | 3 | temporal |
| expense → be related to → clinical trials | 6 |
| expense → be related to → phase 1 clinical trial | 3 |
| negative | neutral | positive |
| 0.062 | 0.837 | 0.101 |
| Raw frequency | 9 |
| Normalized frequency | 0.180 |
| Modifier score | 0.500 |
| Perplexity | 36.536 |